A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT01594229 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: ABT-199
DRUG: Rituximab
DRUG: Bendamustine

Sponsor

AbbVie

Collaborators

[object Object]